Maze Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 |
|---|---|---|---|
| Income Statement | |||
| Revenue | — | $167.5 | — |
| Operating income | -$142.9 | $57.6 | — |
| Net income | -$131.1 | $52.2 | — |
| Cash Flow Statement | |||
| Free cash flow | -$112.7 | $74.8 | — |
| Dividends | $0.0 | $0.0 | — |
Shares outstanding 55.3M · Free float 77.8%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.